AMIC receives license to produce clinical Mo-99 in U.S.
The Advanced Medical Isotope Corporation (AMIC) has executed an exclusive world-wide license for patented technology of a "sub-critical system" relating to generating clinically relevant quantities of radioisotopes, including Mo-99.
In November 2009, AMIC received encouraging results from initial tests conducted at the Idaho Accelerator Center at Idaho State University in Pocatello, and has created a commercial business case for going forward with the enhanced technology.
The Kennewick, Wash.-based company claimed that once the plant is completed, the technology will afford AMIC the opportunity to supply up to 50 percent of the Mo-99 needs of the U.S.
In November 2009, AMIC received encouraging results from initial tests conducted at the Idaho Accelerator Center at Idaho State University in Pocatello, and has created a commercial business case for going forward with the enhanced technology.
The Kennewick, Wash.-based company claimed that once the plant is completed, the technology will afford AMIC the opportunity to supply up to 50 percent of the Mo-99 needs of the U.S.